Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Mycophenolate mofetil (MMF) embryopathy is a malformative syndrome due to the teratogenic effect of MMF, an effective immunosuppressive agent widely used for the prevention of organ rejection after organ transplantation.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for mycophenolate mofetil embryopathy.
4 publications have been identified in PubMed for mycophenolate mofetil embryopathy. Research spans Review / Meta-Analysis (75%) and Other (25%).
Selva-O'Callaghan A (2025). [PMID: 41728064](https://pubmed.ncbi.nlm.nih.gov/41728064/). *Curr Treatm Opt Rheumatol*. [Review / Meta-Analysis]
Selva-O'Callaghan A (2025). [PMID: 40115529](https://pubmed.ncbi.nlm.nih.gov/40115529/). *Curr Treatm Opt Rheumatol*. [Review / Meta-Analysis]
Dubucs C (2024). [PMID: 39296666](https://pubmed.ncbi.nlm.nih.gov/39296666/). *Front Pediatr*. [Review / Meta-Analysis]
Valentini R (2024). [PMID: 38860232](https://pubmed.ncbi.nlm.nih.gov/38860232/). *Int J Womens Dermatol*. [Other]
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 7:49 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center